Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Intensification with Topotecan for Localized Ewing Sarcoma
NCT00618813Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan liposome in Ewing sarcoma and Peripheral Primitive Neuroectodermal Tumor (pPNET), sponsored by Children's Oncology Group. Primary endpoints: Incidence of Death and Incidence Rate of Dose-limiting Toxicity. Started Mar 2008; status: completed.
02
Drugs
topotecan liposome
03
Conditions
Ewing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)
Beyond the preview
Go deeper on NCT00618813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00618813.